cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Drug discovery company announces new U.S. National Cancer Institute contract
October 25th, 2005
Provid Pharmaceuticals Inc. announced the award of a $750,000 phase II SBIR contract by the U.S. National Cancer Institute (NCI). The NCI and Provid will collaborate on a number of oncology targets over the next 2 years. Provid will apply its hypothesis-driven drug discovery chemistry to translate the assay hits into viable drug candidate leads for applications in cancer therapy. These projects emerged from the efforts of the Developmental Therapeutics Program Screening Technologies Branch at NCI, where small molecule assay hits have been identified and are ready for medicinal chemistry validation and optimization. Provid Pharmaceuticals is a...
Source: cancer weekly (2005-10-25)
|
